Subtopic Deep Dive
HER2-Positive Breast Cancer Trastuzumab
Research Guide
What is HER2-Positive Breast Cancer Trastuzumab?
HER2-positive breast cancer trastuzumab refers to the monoclonal antibody trastuzumab targeting HER2 overexpression in breast cancer, used as adjuvant and metastatic therapy to improve survival.
Trastuzumab binds HER2, inhibiting signaling in HER2-amplified tumors. Guidelines define HER2-positive status via testing standards (Wolff et al., 2013, 1776 citations). Next-generation agents like trastuzumab deruxtecan address resistance in pretreated patients (Modi et al., 2019, 1834 citations).
Why It Matters
Trastuzumab established HER2-targeted therapy, boosting survival in 15-20% of breast cancers. NCCN guidelines integrate it with chemotherapy for early and advanced disease (Gradishar et al., 2020, 1606 citations). Enhancements like trastuzumab deruxtecan extend progression-free survival in resistant cases (Modi et al., 2019). St. Gallen consensus tailors its use in early breast cancer management (Coates et al., 2015, 1794 citations).
Key Research Challenges
Trastuzumab Resistance Mechanisms
Resistance arises from HER2 mutations or pathway bypass in metastatic settings. Modi et al. (2019) highlight needs for sequencing agents post-trastuzumab failure. Biomarker identification remains inconsistent across trials.
HER2 Testing Accuracy
IHC and FISH discrepancies affect patient selection. Wolff et al. (2013) updated ASCO/CAP guidelines to standardize testing and reduce false positives. Variability persists in low-expression cases.
Cardiotoxicity Risk Assessment
Trastuzumab causes heart failure, especially with anthracyclines. Gradishar et al. (2020) recommend monitoring in NCCN protocols. Predictive biomarkers for cardiotoxicity are lacking.
Essential Papers
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Rafael G. Amado, Michael Wolf, Marc Peeters et al. · 2008 · Journal of Clinical Oncology · 3.1K citations
Purpose Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating m...
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian et al. · 2020 · Breast Cancer Research · 2.4K citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · 2016 · New England Journal of Medicine · 1.9K citations
Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving r...
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita et al. · 2019 · New England Journal of Medicine · 1.8K citations
Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lun...
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Alan S. Coates, Eric P. Winer, Aron Goldhirsch et al. · 2015 · Annals of Oncology · 1.8K citations
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · 2013 · Archives of Pathology & Laboratory Medicine · 1.8K citations
Purpose.—To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in b...
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham et al. · 2020 · Journal of the National Comprehensive Cancer Network · 1.6K citations
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the t...
Reading Guide
Foundational Papers
Start with Wolff et al. (2013) for HER2 testing standards (1776 citations), then Coates et al. (2015) for therapy consensus (1794 citations) to ground diagnostics and treatment protocols.
Recent Advances
Study Modi et al. (2019) for next-gen trastuzumab deruxtecan in resistant cases (1834 citations) and Gradishar et al. (2020) NCCN updates (1606 citations) for current guidelines.
Core Methods
Core techniques: IHC/FISH for HER2 status (Wolff et al., 2013), progression-free survival analysis in trials (Modi et al., 2019), adjuvant sequencing per consensus (Coates et al., 2015).
How PapersFlow Helps You Research HER2-Positive Breast Cancer Trastuzumab
Discover & Search
Research Agent uses searchPapers and citationGraph on 'trastuzumab HER2 breast cancer' to map 50+ papers, revealing Modi et al. (2019) as a hub with 1834 citations linking to resistance studies. exaSearch uncovers guideline updates like Wolff et al. (2013); findSimilarPapers expands to NCCN evolutions (Gradishar et al., 2020).
Analyze & Verify
Analysis Agent applies readPaperContent to extract efficacy data from Modi et al. (2019), then verifyResponse with CoVe checks claims against Wolff et al. (2013) guidelines. runPythonAnalysis performs GRADE grading on survival meta-data and statistical verification of hazard ratios from trastuzumab trials using pandas for cohort comparisons.
Synthesize & Write
Synthesis Agent detects gaps in resistance biomarkers via contradiction flagging across Coates et al. (2015) and Gradishar et al. (2020). Writing Agent uses latexEditText, latexSyncCitations for guideline summaries, latexCompile for reports, and exportMermaid for therapy sequencing diagrams.
Use Cases
"Analyze survival data from trastuzumab trials in HER2-positive breast cancer"
Analysis Agent → runPythonAnalysis (pandas on extracted HRs from Modi et al. 2019 and Gradishar et al. 2020) → matplotlib survival curves and statistical p-values output.
"Draft LaTeX review on trastuzumab adjuvant therapy guidelines"
Synthesis Agent → gap detection (Coates et al. 2015 vs. Wolff et al. 2013) → Writing Agent latexEditText + latexSyncCitations + latexCompile → formatted PDF with figures.
"Find code for HER2 expression analysis in breast cancer papers"
Research Agent → paperExtractUrls (from Gradishar et al. 2020) → Code Discovery: paperFindGithubRepo → githubRepoInspect → R scripts for biomarker simulation.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on trastuzumab efficacy, structures report with GRADE scores from Analysis Agent on Modi et al. (2019). DeepScan applies 7-step CoVe chain: readPaperContent (Wolff et al. 2013) → verifyResponse → runPythonAnalysis for testing accuracy stats. Theorizer generates hypotheses on resistance from citationGraph linking Coates et al. (2015) to emerging biomarkers.
Frequently Asked Questions
What defines HER2-positive breast cancer for trastuzumab?
HER2-positive requires IHC 3+ or IHC 2+ with ISH amplification per ASCO/CAP guidelines (Wolff et al., 2013).
What are main methods in trastuzumab research?
Methods include randomized trials for efficacy, biomarker assays like FISH/IHC, and cardiotoxicity monitoring in adjuvant settings (Gradishar et al., 2020).
What are key papers on trastuzumab?
Modi et al. (2019) on trastuzumab deruxtecan (1834 citations); Coates et al. (2015) on early breast cancer consensus (1794 citations); Wolff et al. (2013) on testing (1776 citations).
What open problems exist?
Overcoming resistance in metastatic disease, standardizing low HER2 expression testing, and predicting cardiotoxicity lack validated biomarkers (Modi et al., 2019; Gradishar et al., 2020).
Research HER2/EGFR in Cancer Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HER2-Positive Breast Cancer Trastuzumab with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the HER2/EGFR in Cancer Research Research Guide